AN2 TherapeuticsANTX
13F holders, Q4 2024 (December 31)At the end of Q4 2024, 38 institutions reported holding AN2 Therapeutics Inc. (ANTX) in their 13F filings, up 7 from Q3 2024. 9 opened new positions and 6 sold out. The largest holders were BML Capital Management, LLC ($7.9M), Almitas Capital LLC ($1.8M) and Vanguard Group Inc. ($1.4M). 3 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio), Israel Englander (0.0% of Millennium Management's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- AN2 Therapeutics Inc.
- CUSIP
- 037326105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 9 | $3.6M |
| Exits | 6 | $4.4M |
All 13F filers, Q3 2024 → Q4 2024: 4,115,215 shares bought and 4,393,829 shares sold, net −278,614 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 38 holders
| BML Capital Management, LLC | 4.93% | No change | 5,749,432 | $7.9M |
| Almitas Capital LLC | 0.40% | New | 1,313,111 | $1.8M |
| Vanguard Group Inc. | 0.00% | Reduce -0.5% | 1,035,947 | $1.4M |
| Pfizer Inc | 0.04% | — | 715,295 | $987K |
| Renaissance Technologies | 0.00% | Add +36.8% | 579,773 | $800K |
| Peapod Lane Capital LLC | 0.79% | — | 578,825 | $799K |
| Two Sigma Advisers, LP | 0.00% | Add +337.0% | 528,300 | $729K |
| Bank of Montreal | 0.00% | New | 422,077 | $582K |
| Two Sigma Investments, LP | 0.00% | Add +125.1% | 400,332 | $552K |
| Bank of Nova Scotia | 0.00% | New | 394,868 | $545K |
| Bank of America Corp. | 0.00% | Add +2278.0% | 385,475 | $532K |
| Aldebaran Capital, LLC | 0.45% | Add +242.0% | 343,684 | $474K |
| Adage Capital Partners Gp, L.L.C. | 0.00% | No change | 312,615 | $431K |
| BlackRock, Inc. | 0.00% | Add +0.1% | 301,421 | $416K |
| Geode Capital Management, LLC | 0.00% | Add +3.5% | 227,796 | $314K |
| Millennium Management | 0.00% | Reduce -47.4% | 209,366 | $289K |
| Stonepine Capital Management, LLC | 0.22% | New | 196,732 | $271K |
| UBS Group AG | 0.00% | New | 170,292 | $235K |
| Bridgeway Capital Management, LLC | 0.01% | Reduce -17.7% | 162,200 | $224K |
| State Street Corp. | 0.00% | Add +44.3% | 87,002 | $120K |
| Marquette Asset Management, LLC | 0.02% | Add +29.0% | 83,206 | $115K |
| Citadel Advisors | 0.00% | New | 67,994 | $94K |
| Squarepoint Ops LLC | 0.00% | New | 62,441 | $86K |
| Northern Trust Corp. | 0.00% | Add +32.5% | 43,196 | $60K |
| XTX Topco Ltd | 0.00% | Add +44.5% | 34,179 | $47K |
| Captrust Financial Advisors | 0.00% | No change | 28,667 | $40K |
| Schonfeld Strategic Advisors LLC | 0.00% | Reduce -59.3% | 26,900 | $37K |
| Integrated Wealth Concepts LLC | 0.00% | No change | 25,000 | $35K |
| Private Advisor Group, LLC | 0.00% | No change | 22,500 | $31K |
| Qube Research & Technologies Ltd | 0.00% | New | 10,185 | $14K |
| Federated Hermes, Inc. | 0.00% | Add +149.2% | 7,492 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -65.6% | 1,463 | $2K |
| Innovative Advisory Group, LLC | 0.00% | — | 1,170 | $2K |
| BNP Paribas Financial Markets | 0.00% | New | 312 | $431 |
| Morgan Stanley | 0.00% | Reduce -1.0% | 300 | $414 |
| Osaic Holdings, Inc. | 0.00% | No change | 300 | $414 |
| SBI Securities Co., Ltd. | 0.00% | — | 200 | $276 |
| JPMorgan Chase & Co. | 0.00% | Reduce -3.7% | 52 | $72 |
"% of holder's portfolio" is ANTX's weight in each manager's 13F, not the share of AN2 Therapeutics Inc. the manager owns.